Figure 2From: Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trialsIncidence rate ratios for saxagliptin vs control (point estimates and 95% CI) for CV death, myocardial infarction, stroke, and heart failure in the 20-study pool. Numbers in parentheses are total patient-years of exposure (the time up to an event or censoring). CV = cardiovascular; IRR = incidence rate ratio; MACE = major adverse cardiovascular events; SAXA = saxagliptin.Back to article page